Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

On January 14, 2022 Oblique Therapeutics AB reported that key aspects of its AbiProt technology for discovering and developing pharmacologically tailored antibodies against clinically important targets has been granted by the USPTO as US Patent No. 11,161,901 B2 (Press release, Oblique Therapeutics, JAN 14, 2022, View Source [SID1234605491]). The technology uses artificially intelligent molecular probes and mass spectrometry to identify antibody binding sites on clinically relevant targets, many of which have been considered undruggable with antibodies. The AbiProt proteomics technology from Oblique Therapeutics has the potential to bring several novel antibody medicines to large patient populations in multiple disease areas

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbiProt was recently presented in detail in a research article in Science Advances, Rational antibody design for undruggable targets using kinetically controlled biomolecular probes (science.org). The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics’ team.

Owe Orwar, Ph.D., Professor, Founder and CEO of Oblique Therapeutics says:

"We are absolutely thrilled by the news from USPTO. We are today developing a number of programs out of the AbiProt platform with a focus on pain and aggressive cancer. In particular, we have developed a world-leading portfolio of mutant-selective KRAS mAbs showing efficacy in animal models of G13D-mutated colorectal cancer and highly interesting first-in-class mAbs targeting TRPV1 intended as a replacement for opioids in pain management. The aTRPV1 mAb is R&D-partnered with a license-option with a major pharma company."

Carolina Trkulja, Ph.D., Founder and CSO of Oblique Therapeutics says:

"I’m delighted to receive this news from the USPTO and very excited for what the future holds for the AbiProt platform and what it will mean for the patients. This technology has the potential to transform the treatment landscape for several aggressive diseases and bring new hope to these patient populations."

About AbiProt

AbiProt, is a proprietary methodology to identify epitopes on protein targets that have previously proven difficult to address with antibodies. AbiProt can identify high-affinity antibody binding sites in a given protein with single amino acid resolution while the protein resides in its native environment. It is based on using a tailored molecular reporter system and proteomics. The platform yields detailed sequence and structure information for epitope identification and development. Oblique Therapeutics is applying this technology for discovery of a new generation of selective antibody therapeutics targeting cancer and pain.

Science Advances Publication about AbiProt: